ICD-10 Specific code E78.2: Mixed hyperlipidaemia
Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
Translations
| Language | Translation |
|---|---|
English
|
Mixed hyperlipidaemia |
French
|
Hyperlipidémie mixte |
Hierarchical position
| Level | Code | Title | |
|---|---|---|---|
| 1 | IV | Endocrine, nutritional and metabolic diseases | |
| 2 | E70-E90 | Metabolic disorders | |
| 3 | E78 | Disorders of lipoprotein metabolism and other lipidaemias | |
| 4 | E78.2 | Mixed hyperlipidaemia |
Indicated medicines
| Active Ingredient |
|---|
|
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. |
|
Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. Ezetimibe and simvastatin are two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe/simvastatin combination reduces elevated total cholesterol (total-C), LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-HDL-C), and increases high-density lipoprotein cholesterol (HDL-C) through dual inhibition of cholesterol absorption and synthesis. |